How We Support Clinical Care
At TAVRA Biosciences, we focus on defined clinical areas where regenerative therapies may support localized tissue health, function, and recovery. Published clinical literature examining bone marrow–derived mesenchymal stromal cells across joint, soft-tissue, and disc settings emphasizes favorable safety profiles and reports statistically significant reductions in pain and improvements in function.
Contact us for additional Clinical Evidence for complete study design, dosing details, and all citations for mesenchymal stem cell therapy applications.
Based on evidence from more than 100 randomized controlled trials and multiple high-quality systematic reviews and meta-analyses involving over 5,000 patients, locally administered MSC therapy has demonstrated a strong safety profile and meaningful therapeutic benefit across several indications. The most commonly reported adverse event, transient fever, is generally self-limiting and
manageable.
TAVRA builds on this intrinsic safety profile through donor eligibility and screening, validated manufacturing processes, defined xeno-free culture conditions, and a DMSO-free product formulation designed to support safety, consistency, and product quality.
BM-MSCs have the most developed clinical evidence base in knee applications, spanning stem cell injections for knee pain, osteoarthritis, cartilage injury, and ligament repair.
45.6% improvement in WOMAC at 12 months (p<0.001). MRI showed cartilage preservation in MSC group vs progressive worsening in placebo.
BMAC augmentation of ACL reconstruction: accelerated ligamentization on MRI at 3 months; higher IKDC scores at 9 months (81.6 vs 74.6, p=0.048).
The shoulder evidence base is anchored by one of the most compelling long-term datasets in regenerative orthopedics.
100% healing at 6 months vs 67% in controls; 87% structural integrity at 10 years vs 44%. Higher MSC count correlated with better outcomes.
BMAC-augmented rotator cuff repair: retear rate 18% vs 57% (p<0.001). Structurally superior repair confirmed on imaging.
Percutaneous BMAC vs. home exercise: significantly greater improvement in NPS (pain), DASH, and SANE scores at every time interval through 24 months. 73% of BMC patients showed radiographic improvement on imaging.
Back and spine carries the strongest allogeneic evidence outside of knee OA, including the only published allogeneic BM-MSC RCT for disc disease and a 100-patient controlled dataset with 36-month durability.
Rapid, significant improvement in pain and disability; Pfirrmann grading improved in MSC group vs worsened in controls at 12 months; 40% were strong responders; no immune reactions
The hip evidence base draws on BMAC surgical adjunct data, with clinical findings supporting MSC therapy in cartilage repair and pain reduction contexts.
BMAC-augmented labral repair: significantly higher mHHS, iHOT-33, and HOS-SS at 60 months vs no-BMAC controls; differences emerged at 24 months and increased in magnitude through 5 years
5/6 studies showed statistically significant improvement in PROs after MSC injection for hip OA; no major complications; positive radiological changes in 2 studies
Most of the foundational BMAC literature uses variable, point-of-care preparations where MSC content is not standardized and donor age is the patient’s own. Allogeneic BM-MSCs differ in two clinically relevant ways. First, they deliver a defined, consistent cell dose across treatments. Second, preclinical data indicates that MSCs from younger donors demonstrate superior proliferative capacity and paracrine function compared to cells from older donors, which is relevant when treating patients whose autologous cell quality and potency are likely diminished. These considerations are reflected in how the supporting BMAC evidence should be interpreted when evaluating allogeneic products.
